Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Semler Scientific Inc. (SMLR) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Medical Devices
$20.33
+0.00 (0.00%)Did SMLR Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Semler Scientific is one of their latest high-conviction picks.
Based on our analysis of 7 Wall Street analysts, SMLR has a bullish consensus with a median price target of $73.00 (ranging from $60.00 to $86.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $20.33, the median forecast implies a 259.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mark Palmer at Benchmark, projecting a 323.0% upside. Conversely, the most conservative target is provided by Brett Knoblauch at Cantor Fitzgerald, suggesting a 195.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for SMLR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 23, 2025 | Benchmark | Mark Palmer | Buy | Maintains | $86.00 |
| Sep 19, 2025 | Maxim Group | Matthew Galinko | Buy | Maintains | $80.00 |
| Aug 6, 2025 | Cantor Fitzgerald | Brett Knoblauch | Overweight | Maintains | $60.00 |
| Jul 28, 2025 | Cantor Fitzgerald | Brett Knoblauch | Overweight | Initiates | $61.00 |
| Jul 9, 2025 | Maxim Group | Matt Galinko | Buy | Initiates | $95.00 |
| Jul 8, 2025 | Benchmark | Mark Palmer | Buy | Initiates | $101.00 |
| Jan 24, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $71.00 |
| Nov 2, 2022 | B. Riley Securities | Marc Wiesenberger | Neutral | Downgrade | $45.00 |
| May 3, 2022 | B. Riley Securities | Marc Wiesenberger | Buy | Maintains | $60.00 |
| Mar 7, 2022 | B. Riley Securities | Marc Wiesenberger | Buy | Maintains | $70.00 |
| Nov 2, 2021 | B. Riley Securities | Marc Wiesenberger | Buy | Maintains | $145.00 |
| Oct 26, 2021 | B. Riley Securities | Marc Wiesenberger | Buy | Maintains | $175.00 |
| May 4, 2021 | B. Riley Securities | Marc Wiesenberger | Buy | Maintains | $151.00 |
| May 4, 2021 | B. Riley FBR | Buy | Maintains | $N/A | |
| Jun 23, 2020 | B. Riley FBR | Buy | Initiates | $N/A | |
| Jun 23, 2020 | B. Riley Securities | Buy | Initiates | $N/A | |
| Jul 29, 2015 | H.C. Wainwright | Initiates | $N/A | ||
| Jul 29, 2015 | HC Wainwright & Co. | Initiates | $N/A | ||
| Jun 5, 2014 | Aegis Capital | Buy | Initiates | $N/A |
The following stocks are similar to Semler Scientific based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Semler Scientific Inc. has a market capitalization of $310.75M with a P/E ratio of 3.9x. The company generates $36.96M in trailing twelve-month revenue with a 130.8% profit margin.
Revenue growth is -44.6% quarter-over-quarter, while maintaining an operating margin of -72.0% and return on equity of +17.7%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Develops innovative medical diagnostic products.
The company generates revenue by developing and marketing advanced diagnostic technologies, primarily through its flagship product, QuantaFlo, which aids in the early detection of peripheral arterial disease (PAD). By serving healthcare providers and medical practitioners, Semler Scientific enhances diagnostic efficiency and patient outcomes, creating a significant market demand for its user-friendly and cost-effective solutions.
Semler Scientific operates within a crucial intersection of technology and healthcare, emphasizing preventative medicine. Its innovative approach not only meets current healthcare needs but also positions the company for potential growth in medical and technological advancements.
Healthcare
Medical Devices
79
Dr. Douglas Murphy-Chutorian M.D.
United States
2014
Kuehn Law is investigating Semler Scientific (NASDAQ: SMLR) for potential fiduciary breaches by its officers and directors related to undisclosed DOJ investigations and misleading public statements.
Legal investigations into Semler Scientific's officers could signal potential financial and reputational risks, impacting stock performance and investor confidence.
Former Louisiana Attorney General Charles C. Foti, Jr. has been mentioned in news from New York and New Orleans as of December 12, 2025. Further details are not provided.
The mention of a former Attorney General could indicate potential legal developments or regulatory changes, impacting businesses and investment climate in Louisiana.
Wohl & Fruchter LLP is investigating the fairness of Semler Scientific's proposed all-stock merger with Strive Asset Management, offering shareholders 21.05 Strive shares per Semler share.
The investigation into Semler's merger with Strive could indicate potential issues with the deal's fairness, impacting share prices and investor confidence in both companies.
In 2025, the trend of US and Canadian digital asset treasuries (DATs) is reversing, with median stock prices dropping 45% this year, per Bloomberg data.
A 45% drop in stock prices for digital asset treasuries signals potential weakness in the crypto sector, impacting investor sentiment and future valuations.
A class action lawsuit has been filed against Semler Scientific, Inc. (NASDAQ: SMLR) and its officers, as announced by Bronstein, Gewirtz & Grossman, LLC.
The class action lawsuit against Semler Scientific could lead to financial liabilities and impact stock performance, signaling potential risks for current and prospective investors.
Levi & Korsinsky, LLP has filed a class action lawsuit for Semler Scientific, Inc. (NASDAQ: SMLR) investors, alleging securities fraud from March 10, 2021, to April 15, 2025.
The class action lawsuit against Semler Scientific may indicate potential financial instability or mismanagement, affecting stock value and investor confidence.
Based on our analysis of 7 Wall Street analysts, Semler Scientific Inc. (SMLR) has a median price target of $73.00. The highest price target is $86.00 and the lowest is $60.00.
According to current analyst ratings, SMLR has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.33. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict SMLR stock could reach $73.00 in the next 12 months. This represents a 259.1% increase from the current price of $20.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company generates revenue by developing and marketing advanced diagnostic technologies, primarily through its flagship product, QuantaFlo, which aids in the early detection of peripheral arterial disease (PAD). By serving healthcare providers and medical practitioners, Semler Scientific enhances diagnostic efficiency and patient outcomes, creating a significant market demand for its user-friendly and cost-effective solutions.
The highest price target for SMLR is $86.00 from Mark Palmer at Benchmark, which represents a 323.0% increase from the current price of $20.33.
The lowest price target for SMLR is $60.00 from Brett Knoblauch at Cantor Fitzgerald, which represents a 195.1% increase from the current price of $20.33.
The overall analyst consensus for SMLR is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $73.00.
Stock price projections, including those for Semler Scientific Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.